Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
Identifieur interne : 003546 ( PubMed/Corpus ); précédent : 003545; suivant : 003547Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
Auteurs : S. Loi ; S. Michiels ; R. Salgado ; N. Sirtaine ; V. Jose ; D. Fumagalli ; P-L Kellokumpu-Lehtinen ; P. Bono ; V. Kataja ; C. Desmedt ; M J Piccart ; S. Loibl ; C. Denkert ; M J Smyth ; H. Joensuu ; C. SotiriouSource :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2014.
English descriptors
- KwdEn :
- Adult, Aged, Antibodies, Monoclonal, Humanized (therapeutic use), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Biomarkers, Pharmacological (analysis), Biomarkers, Tumor (analysis), Chemotherapy, Adjuvant, Female, Finland, Humans, Lymphocytes, Tumor-Infiltrating (pathology), Middle Aged, Neoplasm Staging, Predictive Value of Tests, Prognosis, Trastuzumab, Treatment Outcome, Triple Negative Breast Neoplasms (diagnosis), Triple Negative Breast Neoplasms (drug therapy), Triple Negative Breast Neoplasms (immunology), Triple Negative Breast Neoplasms (pathology).
- MESH :
- chemical , analysis : Biomarkers, Pharmacological, Biomarkers, Tumor.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized.
- geographic : Finland, Trastuzumab.
- diagnosis : Triple Negative Breast Neoplasms.
- drug therapy : Triple Negative Breast Neoplasms.
- immunology : Triple Negative Breast Neoplasms.
- pathology : Lymphocytes, Tumor-Infiltrating, Triple Negative Breast Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Chemotherapy, Adjuvant, Female, Humans, Middle Aged, Neoplasm Staging, Predictive Value of Tests, Prognosis, Treatment Outcome.
Abstract
We have previously shown the prognostic importance of tumor-infiltrating lymphocytes (TILs) in newly diagnosed triple-negative breast cancer (TNBC) using tumor samples from a large clinical trial cohort. In this study, we aimed to validate these findings and also investigate associations with trastuzumab benefit in HER2-overexpressing disease (HER2+).
DOI: 10.1093/annonc/mdu112
PubMed: 24608200
Links to Exploration step
pubmed:24608200Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.</title><author><name sortKey="Loi, S" sort="Loi, S" uniqKey="Loi S" first="S" last="Loi">S. Loi</name><affiliation><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne,Australia sherene.loi@petermac.org.</nlm:affiliation></affiliation></author><author><name sortKey="Michiels, S" sort="Michiels, S" uniqKey="Michiels S" first="S" last="Michiels">S. Michiels</name><affiliation><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium Service de Biostatistique et D'Epidemiology, Gustave Roussy, Universite Paris-Sud, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Salgado, R" sort="Salgado, R" uniqKey="Salgado R" first="R" last="Salgado">R. Salgado</name><affiliation><nlm:affiliation>Department of Anatomical Pathology, Institut Jules Bordet, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Sirtaine, N" sort="Sirtaine, N" uniqKey="Sirtaine N" first="N" last="Sirtaine">N. Sirtaine</name><affiliation><nlm:affiliation>Department of Anatomical Pathology, Institut Jules Bordet, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Jose, V" sort="Jose, V" uniqKey="Jose V" first="V" last="Jose">V. Jose</name><affiliation><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Fumagalli, D" sort="Fumagalli, D" uniqKey="Fumagalli D" first="D" last="Fumagalli">D. Fumagalli</name><affiliation><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Kellokumpu Lehtinen, P L" sort="Kellokumpu Lehtinen, P L" uniqKey="Kellokumpu Lehtinen P" first="P-L" last="Kellokumpu-Lehtinen">P-L Kellokumpu-Lehtinen</name><affiliation><nlm:affiliation>Department of Oncology, Tampere University Hospital, Tampere.</nlm:affiliation></affiliation></author><author><name sortKey="Bono, P" sort="Bono, P" uniqKey="Bono P" first="P" last="Bono">P. Bono</name><affiliation><nlm:affiliation>Department of Oncology, Helsinki University Central Hospital, Helsinki.</nlm:affiliation></affiliation></author><author><name sortKey="Kataja, V" sort="Kataja, V" uniqKey="Kataja V" first="V" last="Kataja">V. Kataja</name><affiliation><nlm:affiliation>Cancer Center, Kuopio University Hospital, Kuopio, Finland.</nlm:affiliation></affiliation></author><author><name sortKey="Desmedt, C" sort="Desmedt, C" uniqKey="Desmedt C" first="C" last="Desmedt">C. Desmedt</name><affiliation><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Piccart, M J" sort="Piccart, M J" uniqKey="Piccart M" first="M J" last="Piccart">M J Piccart</name><affiliation><nlm:affiliation>Department of Medicine, Institut Jules Bordet, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Loibl, S" sort="Loibl, S" uniqKey="Loibl S" first="S" last="Loibl">S. Loibl</name><affiliation><nlm:affiliation>German Breast Group, Neu-Isenburg.</nlm:affiliation></affiliation></author><author><name sortKey="Denkert, C" sort="Denkert, C" uniqKey="Denkert C" first="C" last="Denkert">C. Denkert</name><affiliation><nlm:affiliation>Charité University Hospital, Institute of Pathology, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Smyth, M J" sort="Smyth, M J" uniqKey="Smyth M" first="M J" last="Smyth">M J Smyth</name><affiliation><nlm:affiliation>Immunology in Cancer and Infection Laboratory, Queensland Institute of Medical Research (QIMR) Berghofer Medical Research Institute; School of Medicine, University of Queensland, Herston, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Joensuu, H" sort="Joensuu, H" uniqKey="Joensuu H" first="H" last="Joensuu">H. Joensuu</name><affiliation><nlm:affiliation>Department of Oncology, Helsinki University Central Hospital, Helsinki.</nlm:affiliation></affiliation></author><author><name sortKey="Sotiriou, C" sort="Sotiriou, C" uniqKey="Sotiriou C" first="C" last="Sotiriou">C. Sotiriou</name><affiliation><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24608200</idno><idno type="pmid">24608200</idno><idno type="doi">10.1093/annonc/mdu112</idno><idno type="wicri:Area/PubMed/Corpus">003546</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003546</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.</title><author><name sortKey="Loi, S" sort="Loi, S" uniqKey="Loi S" first="S" last="Loi">S. Loi</name><affiliation><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne,Australia sherene.loi@petermac.org.</nlm:affiliation></affiliation></author><author><name sortKey="Michiels, S" sort="Michiels, S" uniqKey="Michiels S" first="S" last="Michiels">S. Michiels</name><affiliation><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium Service de Biostatistique et D'Epidemiology, Gustave Roussy, Universite Paris-Sud, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Salgado, R" sort="Salgado, R" uniqKey="Salgado R" first="R" last="Salgado">R. Salgado</name><affiliation><nlm:affiliation>Department of Anatomical Pathology, Institut Jules Bordet, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Sirtaine, N" sort="Sirtaine, N" uniqKey="Sirtaine N" first="N" last="Sirtaine">N. Sirtaine</name><affiliation><nlm:affiliation>Department of Anatomical Pathology, Institut Jules Bordet, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Jose, V" sort="Jose, V" uniqKey="Jose V" first="V" last="Jose">V. Jose</name><affiliation><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Fumagalli, D" sort="Fumagalli, D" uniqKey="Fumagalli D" first="D" last="Fumagalli">D. Fumagalli</name><affiliation><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Kellokumpu Lehtinen, P L" sort="Kellokumpu Lehtinen, P L" uniqKey="Kellokumpu Lehtinen P" first="P-L" last="Kellokumpu-Lehtinen">P-L Kellokumpu-Lehtinen</name><affiliation><nlm:affiliation>Department of Oncology, Tampere University Hospital, Tampere.</nlm:affiliation></affiliation></author><author><name sortKey="Bono, P" sort="Bono, P" uniqKey="Bono P" first="P" last="Bono">P. Bono</name><affiliation><nlm:affiliation>Department of Oncology, Helsinki University Central Hospital, Helsinki.</nlm:affiliation></affiliation></author><author><name sortKey="Kataja, V" sort="Kataja, V" uniqKey="Kataja V" first="V" last="Kataja">V. Kataja</name><affiliation><nlm:affiliation>Cancer Center, Kuopio University Hospital, Kuopio, Finland.</nlm:affiliation></affiliation></author><author><name sortKey="Desmedt, C" sort="Desmedt, C" uniqKey="Desmedt C" first="C" last="Desmedt">C. Desmedt</name><affiliation><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Piccart, M J" sort="Piccart, M J" uniqKey="Piccart M" first="M J" last="Piccart">M J Piccart</name><affiliation><nlm:affiliation>Department of Medicine, Institut Jules Bordet, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Loibl, S" sort="Loibl, S" uniqKey="Loibl S" first="S" last="Loibl">S. Loibl</name><affiliation><nlm:affiliation>German Breast Group, Neu-Isenburg.</nlm:affiliation></affiliation></author><author><name sortKey="Denkert, C" sort="Denkert, C" uniqKey="Denkert C" first="C" last="Denkert">C. Denkert</name><affiliation><nlm:affiliation>Charité University Hospital, Institute of Pathology, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Smyth, M J" sort="Smyth, M J" uniqKey="Smyth M" first="M J" last="Smyth">M J Smyth</name><affiliation><nlm:affiliation>Immunology in Cancer and Infection Laboratory, Queensland Institute of Medical Research (QIMR) Berghofer Medical Research Institute; School of Medicine, University of Queensland, Herston, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Joensuu, H" sort="Joensuu, H" uniqKey="Joensuu H" first="H" last="Joensuu">H. Joensuu</name><affiliation><nlm:affiliation>Department of Oncology, Helsinki University Central Hospital, Helsinki.</nlm:affiliation></affiliation></author><author><name sortKey="Sotiriou, C" sort="Sotiriou, C" uniqKey="Sotiriou C" first="C" last="Sotiriou">C. Sotiriou</name><affiliation><nlm:affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Biomarkers, Pharmacological (analysis)</term><term>Biomarkers, Tumor (analysis)</term><term>Chemotherapy, Adjuvant</term><term>Female</term><term>Finland</term><term>Humans</term><term>Lymphocytes, Tumor-Infiltrating (pathology)</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Predictive Value of Tests</term><term>Prognosis</term><term>Trastuzumab</term><term>Treatment Outcome</term><term>Triple Negative Breast Neoplasms (diagnosis)</term><term>Triple Negative Breast Neoplasms (drug therapy)</term><term>Triple Negative Breast Neoplasms (immunology)</term><term>Triple Negative Breast Neoplasms (pathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Biomarkers, Pharmacological</term><term>Biomarkers, Tumor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Finland</term><term>Trastuzumab</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Triple Negative Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Triple Negative Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Triple Negative Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lymphocytes, Tumor-Infiltrating</term><term>Triple Negative Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Chemotherapy, Adjuvant</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Predictive Value of Tests</term><term>Prognosis</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We have previously shown the prognostic importance of tumor-infiltrating lymphocytes (TILs) in newly diagnosed triple-negative breast cancer (TNBC) using tumor samples from a large clinical trial cohort. In this study, we aimed to validate these findings and also investigate associations with trastuzumab benefit in HER2-overexpressing disease (HER2+).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24608200</PMID><DateCreated><Year>2014</Year><Month>07</Month><Day>26</Day></DateCreated><DateCompleted><Year>2015</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>8</Issue><PubDate><Year>2014</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title><ISOAbbreviation>Ann. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.</ArticleTitle><Pagination><MedlinePgn>1544-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdu112</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We have previously shown the prognostic importance of tumor-infiltrating lymphocytes (TILs) in newly diagnosed triple-negative breast cancer (TNBC) using tumor samples from a large clinical trial cohort. In this study, we aimed to validate these findings and also investigate associations with trastuzumab benefit in HER2-overexpressing disease (HER2+).</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">A prospective-retrospective study was conducted using samples from the FinHER adjuvant, phase III trial that enrolled 1010 early-stage BC patients, 778 of whom were HER2-nonamplified. Those with HER2+ disease (n = 232) were randomized to 9 weeks of trastuzumab or no trastuzumab in addition to chemotherapy. Two pathologists independently quantified stromal TILs in 935 (92.6%) available slides. The primary end point of distant disease-free survival (DDFS) and interactions with trastuzumab were studied in Cox regression models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Confirming our previous findings, in TNBC (n = 134) each 10% increase in TILs was significantly associated with decreased distant recurrence in TNBC; for DDFS the hazard ratio adjusted for clinicopathological factors: 0.77; 95% confidence interval (CI) 0.61-0.98, P = 0.02. In HER2+ BC (n = 209), each 10% increase in lymphocytic infiltration was significantly associated with decreased distant recurrence in patients randomized to the trastuzumab arm (DDFS P interaction = 0.025).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Higher levels of TILs present at diagnosis were significantly associated with decreased distant recurrence rates in primary TNBC. These results confirm our previous data and further support that TILs should be considered as a robust prognostic factor in this BC subtype. We also report for the first time an association between higher levels of TILs and increased trastuzumab benefit in HER2+ disease. Further research into why some TN and HER2+ BCs can or cannot generate a host antitumor immune response and how trastuzumab can favorably alter the immune microenvironment is warranted.</AbstractText><CopyrightInformation>© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Loi</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne,Australia sherene.loi@petermac.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michiels</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium Service de Biostatistique et D'Epidemiology, Gustave Roussy, Universite Paris-Sud, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salgado</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anatomical Pathology, Institut Jules Bordet, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sirtaine</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Anatomical Pathology, Institut Jules Bordet, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jose</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fumagalli</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kellokumpu-Lehtinen</LastName><ForeName>P-L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Department of Oncology, Tampere University Hospital, Tampere.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bono</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Oncology, Helsinki University Central Hospital, Helsinki.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kataja</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Cancer Center, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desmedt</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piccart</LastName><ForeName>M J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Institut Jules Bordet, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loibl</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>German Breast Group, Neu-Isenburg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denkert</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Charité University Hospital, Institute of Pathology, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smyth</LastName><ForeName>M J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Immunology in Cancer and Infection Laboratory, Queensland Institute of Medical Research (QIMR) Berghofer Medical Research Institute; School of Medicine, University of Queensland, Herston, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joensuu</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Oncology, Helsinki University Central Hospital, Helsinki.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sotiriou</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Oncol</MedlineTA><NlmUniqueID>9007735</NlmUniqueID><ISSNLinking>0923-7534</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054316">Biomarkers, Pharmacological</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>P188ANX8CK</RegistryNumber><NameOfSubstance UI="D000068878">Trastuzumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Oncol. 2014 Aug;25(8):1455-6</RefSource><PMID Version="1">24950980</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054316" MajorTopicYN="Y">Biomarkers, Pharmacological</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="Y">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005387" MajorTopicYN="N" Type="Geographic">Finland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016246" MajorTopicYN="N">Lymphocytes, Tumor-Infiltrating</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068878" MajorTopicYN="N">Trastuzumab</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TILs</Keyword><Keyword MajorTopicYN="N">biomarkers trastuzumab efficacy</Keyword><Keyword MajorTopicYN="N">breast cancer</Keyword><Keyword MajorTopicYN="N">lymphocytic infiltration</Keyword><Keyword MajorTopicYN="N">prediction</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24608200</ArticleId><ArticleId IdType="pii">mdu112</ArticleId><ArticleId IdType="doi">10.1093/annonc/mdu112</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003546 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003546 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24608200
|texte= Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24608200" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |